Cited by

• Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations.

  Yang L, Shen K, Zhang M, Zhang W, Cai H, Lin L, Long X, Xing S, Tang Y, Xiong J, Wang J, Li D, Zhou J, Xiao M. Yang L, et al. Front Oncol. 2019 Oct 24;9:1133. doi: 10.3389/fonc.2019.01133. eCollection 2019. Front Oncol. 2019. PMID: 31709191 Free PMC article.
• Identification of distinct loci for de novo DNA methylation by DNMT3A and DNMT3B during mammalian development.

  Yagi M, Kabata M, Tanaka A, Ukai T, Ohta S, Nakabayashi K, Shimizu M, Hata K, Meissner A, Yamamoto T, Yamada Y. Yagi M, et al. Nat Commun. 2020 Jun 24;11(1):3199. doi: 10.1038/s41467-020-16989-w. Nat Commun. 2020. PMID: 32581223 Free PMC article.
• Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.

  Antherieu G, Bidet A, Huet S, Hayette S, Migeon M, Boureau L, Sujobert P, Thomas X, Ghesquières H, Pigneux A, Heiblig M. Antherieu G, et al. Cancers (Basel). 2021 May 10;13(9):2272. doi: 10.3390/cancers13092272. Cancers (Basel). 2021. PMID: 34068470 Free PMC article.
• Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.

  Fioretti T, Cevenini A, Zanobio M, Raia M, Sarnataro D, Salvatore F, Esposito G. Fioretti T, et al. Cell Oncol (Dordr). 2019 Dec;42(6):829-845. doi: 10.1007/s13402-019-00468-6. Epub 2019 Sep 6. Cell Oncol (Dordr). 2019. PMID: 31493143
• Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.

  Sayar H, Liu Y, Gao R, Zaid MA, Cripe LD, Weisenbach J, Sargent KJ, Nassiri M, Li L, Konig H, Suvannasankha A, Pan F, Shanmugam R, Goswami C, Kapur R, Xu M, Boswell HS. Sayar H, et al. Oncotarget. 2017 Dec 25;9(5):5703-5715. doi: 10.18632/oncotarget.23655. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464028 Free PMC article.